Vaxzines - Kurva vs Kuva?

1min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Noah Smith: A vaxcine company now that's taken a notably different approach to two very successful vaxzines, and it's come up short. What's this going to mean for vaxing development going forward? He says if you know that works and this one has problems, i think a lot of the field is just going to go with the modifications.Smith: We've still got to watch for the second generation from kuva. There are still other vacines that are in development, and there's going to be more results coming from then.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.

News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.